← Eichor
Study identifier: NCT07245329 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effect of Full-House ESS With Nasopharyngeal Lymphoid Tissue Ablation on Nasal Polyps

Condition: Nasal Polyps  ·  Sponsor: Tongji Hospital

PhaseNA
Planned participants32
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

This study is designed to evaluate whether the addition of nasopharyngeal lymphoid tissue ablation to full-house endoscopic sinus surgery (ESS) provides superior control of nasal mucosa inflammation compared to full-house ESS alone in patients with nasal polyps. Thirty-two adult participants will be randomly assigned to undergo either full-house ESS only or full-house ESS combined with nasopharyngeal lymphoid tissue ablation. The primary outcome will be assessed through changes in inflammatory cell profiles at 1, 3, and 6 months postoperatively. Secondary outcomes include inflammatory cytokine levels, symptom scores, endoscopic findings, polyp recurrence rates, and safety measures.

This description comes directly from the study's public registry record.

Talk to the study team

Yin Yao  ·  86 15071077020  ·  Dr.yaoyin@hotmail.com

Xing-Liang Wu  ·  86 15131662389  ·  15131662389@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Tongji Hospital of Tongji Medical College of Huazhong University of Science and TechnologyWuhan, Hubei, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07245329